What is the association between vulvar problems and ankylosing spondylitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Link Between Vulval Issues and Ankylosing Spondylitis

Women with ankylosing spondylitis experience significantly higher rates of vulvovaginal and urogenital problems, including sexual dysfunction, urethritis, vaginitis, and genital atrophy, driven by chronic inflammation, structural changes, and disease-related factors.

Specific Vulval and Urogenital Manifestations

Infectious Complications

Urogenital infections occur at substantially elevated rates in women with AS:

  • Urethral syndrome affects approximately 47% of women with AS (15 of 32 patients), with Chlamydia trachomatis being the predominant pathogen 1
  • Urethritis alone or combined with vaginitis represents the primary infectious pattern
  • Women with urogenital infections demonstrate significantly higher ESR, CRP levels, enthesopathy rates, and spinal involvement compared to non-infected AS patients 1

Sexual Dysfunction

Sexual dysfunction represents a major but underrecognized manifestation:

  • The pooled prevalence of sexual dysfunction in women with AS is 44%, with significantly lower Female Sexual Function Index (FSFI) scores across all domains compared to healthy controls 2
  • All FSFI subscale scores (arousal, lubrication, orgasm, pain, desire) are significantly impaired 3
  • Frequency of sexual intercourse is markedly reduced in women with AS 3

Structural Vulvovaginal Changes

  • Genital atrophy associated with disease duration contributes to persistent vulval dysfunction 2
  • Structural changes compound the functional impairments from inflammation and pain

Pathophysiological Mechanisms

The vulval manifestations arise through multiple interconnected pathways:

Inflammatory Mechanisms:

  • Chronic systemic inflammation causes endothelial dysfunction affecting genital tissues
  • Neuroendocrine alterations disrupt normal physiological sexual response
  • Elevated inflammatory markers (ESR, CRP) correlate directly with urogenital infection severity 1

Physical Disease Factors:

  • Pain, functional limitation, and reduced spinal mobility directly compromise sexual activity 2, 3
  • Disease activity (measured by BASDAI) correlates negatively with sexual function
  • Spinal mobility restrictions (BASMI scores) inversely correlate with FSFI scores 3

Psychological Burden:

  • Depression scores are significantly higher in AS patients and correlate with worse sexual function 3
  • Body image disturbance, anxiety, and psychological distress mediate sexual dysfunction 2
  • Depression specifically reduces desire and arousal domains of sexual function 3

Clinical Assessment Approach

When evaluating vulval issues in AS patients, systematically assess:

Disease Activity Parameters:

  • ESR and CRP levels (elevated in urogenital infections) 1
  • BASDAI scores (correlate with sexual dysfunction)
  • Spinal mobility (BASMI) and functional status (BASFI)
  • Presence of enthesopathy and spinal involvement

Specific Vulvovaginal Evaluation:

  • Screen for urethral syndrome symptoms
  • Test for Chlamydia trachomatis in symptomatic patients 1
  • Assess for vaginitis and structural genital changes
  • Evaluate sexual function using validated instruments (FSFI)

Psychosocial Factors:

  • Depression screening (Beck Depression Inventory)
  • Quality of life assessment (SF-36)
  • Body image concerns
  • Relationship and intimacy impact

Management Implications

Coordinate care between rheumatology and gynecology/urology as emphasized in current guidelines for managing extra-articular manifestations 4, 5. The 2023 PANLAR guidelines specifically highlight that extra-musculoskeletal manifestations require coordinated specialist management 4.

Treat underlying AS aggressively:

  • Optimize disease activity control to reduce inflammatory burden
  • Address pain and functional limitations that directly impair sexual function
  • Consider that better disease control correlates with improved sexual function 3

Screen and treat urogenital infections promptly:

  • Maintain high suspicion for Chlamydia trachomatis in symptomatic patients
  • Recognize that urogenital infection correlates with higher disease activity 1

Address psychological comorbidities:

  • Screen for and treat depression, which independently worsens sexual dysfunction 3
  • Consider psychological support as part of comprehensive management

Critical Caveats

  • Sexual dysfunction occurs even without marked hip involvement or severe body image impairment, so screen all women with AS regardless of disease severity 3
  • These issues are systematically underrecognized and neglected in routine care—proactive screening should be standard practice 2, 3
  • The relationship between AS and vulval problems is bidirectional: infections may worsen disease activity while disease activity predisposes to infections 1

References

Related Questions

What is the recommended management strategy for ankylosing spondylitis?
How do you perform a clinical examination for ankylosing spondylitis?
Can fluoroquinolones be prescribed to patients with ankylosing spondylitis?
Could my calf and hamstring muscle cramps that occurred before the disc protrusion be caused by my ankylosing spondylitis?
How should I manage a patient with ankylosing spondylitis who has thrombocytopenia and leukopenia?
What is the recommended treatment for peritonitis?
What is the appropriate evaluation and management for a patient with a one‑week history of dizziness and a 19 mmHg systolic blood pressure difference between the right and left arms, with otherwise normal bilateral blood pressures?
In a 40-year-old woman with progressive dyspnea, a 20‑pack‑year smoking history, normal vital signs, diffuse thin‑walled cysts on chest CT including the costophrenic angles, a renal angiomyolipoma, negative serology for connective tissue disease, and a serum vascular endothelial growth factor‑D level of 1200 pg/mL, what is the most likely diagnosis?
In a 22-year-old man with a history of lithium, quetiapine, and fluoxetine use who develops malignant hyperthermia after succinylcholine administration, presenting with fever, tachycardia, hypotension, diffuse muscular rigidity, rising end‑tidal CO₂, elevated plateau pressures, and severe respiratory acidosis, what is the next best treatment?
What is the appropriate dose of metoprolol for supraventricular tachycardia?
What is the recommended ampicillin dosing regimen for meningitis coverage in adults, children, and neonates?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.